These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22204226)

  • 21. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation.
    Schwartz NE; Albers GW
    Stroke; 2010 Jun; 41(6):1307-9. PubMed ID: 20395603
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabigatran in clinical practice.
    Nagarakanti R; Ellis CR
    Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of anticoagulation control in atrial fibrillation.
    Lane DA; Lip GY
    Lancet; 2010 Sep; 376(9745):935-7. PubMed ID: 20801499
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
    Weimar C; Hohnloser SH; Eikelboom JW; Diener HC
    Curr Neurol Neurosci Rep; 2012 Feb; 12(1):17-23. PubMed ID: 21960064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
    Ferreira J; Ezekowitz MD; Connolly SJ; Brueckmann M; Fraessdorf M; Reilly PA; Yusuf S; Wallentin L;
    Eur J Heart Fail; 2013 Sep; 15(9):1053-61. PubMed ID: 23843099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dabigatran versus warfarin for patients with non-valvular atrial fibrillation: is the patient the winner?
    Grave S
    Aust Nurs J; 2011 Dec-2012 Jan; 19(6):30-3. PubMed ID: 22329103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.
    Pink J; Lane S; Pirmohamed M; Hughes DA
    BMJ; 2011 Oct; 343():d6333. PubMed ID: 22042753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation.
    Aalbers J; Bryer A; Klug E
    Cardiovasc J Afr; 2010; 21(6):341. PubMed ID: 21135985
    [No Abstract]   [Full Text] [Related]  

  • 33. Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice.
    Heidbuchel H; Verhamme P
    Acta Cardiol; 2010 Oct; 65(5):491-7. PubMed ID: 21125969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dabigatran: a new anticoagulant for stroke prevention in patients with atrial fibrillation.
    Weachter R
    Mo Med; 2012; 109(2):146-9. PubMed ID: 22675797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The results of the RE-lY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation].
    Vojácek J
    Vnitr Lek; 2009 Nov; 55(11):1085-8. PubMed ID: 20017441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights and results from the RE-LY trial.
    Cardiovasc J Afr; 2011; 22(5):284-6. PubMed ID: 21983958
    [No Abstract]   [Full Text] [Related]  

  • 37. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
    Lip GY; Lane DA
    Am J Med; 2010 Sep; 123(9):785-9. PubMed ID: 20655037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM; Qureshi AI
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ
    Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.